# Novartis Pharmaceuticals Corporation – FDA Inspection, Jun 25, 2025

Source: https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/d76eeb82-f498-4fa6-9c50-25c0625a0d59
Source feed: FDA_Inspections

> FDA inspection 1276202 of Novartis Pharmaceuticals Corporation, June 25, 2025. Classification: No Action Indicated (NAI). 30 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1276202
- Company Name: Novartis Pharmaceuticals Corporation
- Inspection Date: 2025-06-25
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Bioresearch Monitoring
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1328008 - 2026-06-24
- FDA Inspection 1263198 - 2025-03-03
- FDA Inspection 1257911 - 2024-11-19
- [FDA Inspection 1248433 - 2024-08-29](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/ccf044c3-0b3e-481e-97b9-66c1a8ca3e62)
- FDA Inspection 1230105 - 2024-06-27

## Related Officers

- [Company Rep](https://www.keypedia.com/people/kellie-r-riggs/556818c6-eb9a-48a5-9630-aba7a807ec07)
- [Issuing Officer](https://www.keypedia.com/people/matthew-r-coleman/6fc13ec4-a609-4c3c-961f-16cba13a3a3a)

Company: https://www.keypedia.com/companies/novartis-pharmaceuticals-corporation/aa4c85c1-794a-407a-8eb3-8802c196795b

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
